- Home
- ANNX vs NODK Comparison
ANNX vs NODK Comparison
Compare ANNX & NODK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- NODK
- Stock Information
- Founded
- ANNX 2011
- NODK 1946
- Country
- ANNX United States
- NODK United States
- Employees
- ANNX N/A
- NODK N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- NODK Property-Casualty Insurers
- Sector
- ANNX Health Care
- NODK Finance
- Exchange
- ANNX Nasdaq
- NODK Nasdaq
- Market Cap
- ANNX 253.8M
- NODK 259.5M
- IPO Year
- ANNX 2020
- NODK 2017
- Fundamental
- Price
- ANNX $2.06
- NODK $13.39
- Analyst Decision
- ANNX Strong Buy
- NODK
- Analyst Count
- ANNX 5
- NODK 0
- Target Price
- ANNX $13.00
- NODK N/A
- AVG Volume (30 Days)
- ANNX 1.2M
- NODK 13.4K
- Earning Date
- ANNX 08-14-2025
- NODK 08-08-2025
- Dividend Yield
- ANNX N/A
- NODK N/A
- EPS Growth
- ANNX N/A
- NODK N/A
- EPS
- ANNX N/A
- NODK 0.07
- Revenue
- ANNX N/A
- NODK $310,389,000.00
- Revenue This Year
- ANNX N/A
- NODK N/A
- Revenue Next Year
- ANNX N/A
- NODK N/A
- P/E Ratio
- ANNX N/A
- NODK $190.00
- Revenue Growth
- ANNX N/A
- NODK N/A
- 52 Week Low
- ANNX $1.29
- NODK $12.01
- 52 Week High
- ANNX $7.85
- NODK $17.24
- Technical
- Relative Strength Index (RSI)
- ANNX 38.44
- NODK 60.10
- Support Level
- ANNX $2.06
- NODK $12.22
- Resistance Level
- ANNX $2.36
- NODK $13.38
- Average True Range (ATR)
- ANNX 0.17
- NODK 0.31
- MACD
- ANNX -0.03
- NODK 0.10
- Stochastic Oscillator
- ANNX 1.52
- NODK 99.15
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.